BRIEF RESEARCH REPORT article
Front. Cardiovasc. Med.
Sec. Clinical and Translational Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1668882
Role of Heparin-induced HGF Release at the Acute Phase of STEMI
Provisionally accepted- 1Hospices Civils de Lyon, Lyon, France
- 2Cardiovasculaire Metabolisme Diabetologie et Nutrition, Pierre-Bénite, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Reperfusion injury remains a major limitation in the management of ST-segment elevation myocardial infarction (STEMI). Despite numerous preclinical successes, cardioprotective strategies have largely failed in clinical translation. Heparin, routinely administered in STEMI, may exert protective effects beyond anticoagulation through rapid release of hepatocyte growth factor (HGF), a known cardioprotective agent. Methods: We analyzed 229 STEMI patients undergoing primary percutaneous coronary intervention (PCI) from the HIBISCUS-STEMI cohort. Serum HGF levels were measured by ELISA at five time points post-admission. In a subset of four patients, HGF levels were assessed before and 30 minutes after heparin injection. To test the functional effect of HGF, a murine ischemia-reperfusion model was used where recombinant HGF (0.3 mg/kg) or saline was administered intravenously five minutes before reperfusion. Infarct size was quantified by TTC staining. Results: A rapid and significant rise in HGF levels was observed at admission (median 8750 pg/mL), declining thereafter. In the subset analysis, heparin administration increased HGF levels from 356 ± 77 to 5026 ± 1957 pg/mL (p < 0.05). In mice, HGF administration significantly reduced infarct size compared to controls (48% vs. 58%, p = 0.0023), with no difference in area at risk. Discussion: This study demonstrates that heparin induces a rapid and substantial increase in circulating HGF in STEMI patients, potentially mediating cardioprotection during reperfusion. These findings suggest that co-medications like heparin may confound cardioprotective trials and should be considered in future translational strategies.
Keywords: Hepatocyte growth factor (HGF), STEMI (myocardial infarction), Heparin, Cardioprotection, Met
Received: 18 Jul 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Leboube, Paccalet, BRUN, MOULIN, Pillot, Bidaux, MECHTOUFF, THIBAULT, BOCHATON and CROLA DA SILVA. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Simon Leboube, simon.leboube@chu-lyon.fr
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.